Poolbeg Pharma PLC POLB
LSE · United Kingdom · Health Technology
GBp 7.35-0.05 (-0.68%)
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Poolbeg Pharma PLC (AIM:POLB) CEO Jeremy Skillington spoke with Proactive's Stephen Gunnion about the company's interim results for the first half of 2026, progress with POLB 001 and the milestones investors can expect as its clinical development programme advances. Skillington said Poolbeg Pharma made "incredible progress" during the period, successfully transitioning POLB 001 from trial preparation into active clinical development. The programme is being studied in relapsed or refractory multiple myeloma patients, aiming to prevent cytokine release syndrome associated with cancer therapy. Th
Poolbeg Pharma PLC (AIM:POLB) CEO Jeremy Skillington spoke with Proactive's Stephen Gunnion after a positive interim safety review of its TOPICAL clinical trial targeting cytokine release syndrome (CRS) linked to cancer therapies. The review recommended the trial continue unchanged, with recruitment ongoing at leading UK sites and further sites being activated. Skillington said the latest data adds to the preclinical evidence, previous trial data and intellectual property supporting POLB 001, while Poolbeg continues discussions with potential pharmaceutical partners. He said the focus now is o
Galliford Try (LSE:GFRD) has secured places across all five regional lots of a £9.5 billion public sector construction framework covering schools, colleges, universities and healthcare buildings across Great Britain. The framework can run for up to eight years. Poolbeg Pharma (AIM:POLB) has received a Notice of Allowance from the Israeli Patent Office for its POLB 001 cytokine release syndrome patent, following earlier grants in Europe, Australia and Canada. The growing patent estate is expected to strengthen the drug's appeal to potential commercial partners. Tertiary Minerals (AIM:TYM) has r
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.